第三腰椎骨骼肌指数在消化系统疾病中的研究进展

doi:10.3969/j.issn.1004-583X.2025.08.011

摘要/Abstract

摘要：

第三腰椎骨骼肌指数是基于计算机断层扫描或磁共振成像在第三腰椎水平测量的骨骼肌面积标准化后的指标,目前广泛应用于评估肌肉减少症、营养状况以及疾病预后预测。本文就第三腰椎骨骼肌指数的测量及其在消化系统疾病中的研究进展进行综述,旨在为疾病的预后预测提供有价值的参考。

中图分类号:

R725.7

王先耀, 姚秋艳, 张俊梅, 字颖, 龙均, 施荣杰. 第三腰椎骨骼肌指数在消化系统疾病中的研究进展[J]. 临床荟萃, 2025, 40(8): 731-735.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.lchc.cn/CN/10.3969/j.issn.1004-583X.2025.08.011

https://www.lchc.cn/CN/Y2025/V40/I8/731

参考文献 42

[1]	Frontera WR, Ochala J. Skeletal muscle: A brief review of structure and function[J]. Calcif Tissue Int, 2015, 96(3):183-195.
[2]	Fu Y, Zhao S, Zhang C, et al. The impact of sarcopenia on postoperative complications and survival outcomes after robotic colorectal cancer surgery: A study based on single-center propensity score matching[J]. J Robot Surg, 2024, 19(1):13. doi: 10.1007/s11701-024-02133-z pmid: 39615012
[3]	Sugimura K, Miyata H, Kanemura T, et al. Impact of preoperative skeletal muscle mass and physical performance on short-term and long-term postoperative outcomes in patients with esophageal cancer after esophagectomy[J]. Ann Gastroenterol Surg, 2022, 6(5):623-632. doi: 10.1002/ags3.12560 pmid: 36091312
[4]	Liu C, Li Y, Xu Y, et al. The impact of preoperative skeletal muscle mass index-defined sarcopenia on postoperative complications and survival in gastric cancer: An updated meta-analysis[J]. Eur J Surg Oncol, 2025, 51(3):109569.
[5]	Mourtzakis M, Prado CM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care[J]. Appl Physiol Nutr Metab, 2008, 33(5):997-1006.
[6]	Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in pants with solid tumours of the respiratory and gastrointestinal tracts: A population-based study[J]. Lancet Oncol, 2008, 9(7):629-635.
[7]	Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: Revised European consensus on definition and diagnosis[J]. Age Ageing, 2019, 48(1):16-31. doi: 10.1093/ageing/afy169 pmid: 30312372
[8]	Iritani S, Imai K, Takai K, et al. Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma[J]. J Gastroenterol, 2014, 50 (3): 323-332.
[9]	Cho K, Oh D, Kim T, et al. Skeletal muscle depletion to predict survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy[J]. J Clin Oncol, 2017, 35 (4_suppl): 460-460.
[10]	Carey EJ, Lai JC, Wang CW, et al. A multicenter study to define sarcopenia in patients with end-stage liver disease[J]. Liver Transpl, 2017, 23(5):625-633.
[11]	Zeng X, Shi ZW, Yu JJ, et al. Sarcopenia as a prognostic predictor of liver cirrhosis: A multicentre study in China[J]. J Cachexia Sarcopenia Muscle, 2021, 12(6):1948-1958. doi: 10.1002/jcsm.12797 pmid: 34520115
[12]	Chinese Society of Gastroenterology,Chinese Medical Association. Chinese consensus on the management of liver cirrhosis[J]. J Dig Dis, 2024, 25(6):332-352.
[13]	Chen H, Yang C, Yan S, et al. Sarcopenia in cirrhosis: From pathophysiology to interventional therapy[J]. Exp Gerontol, 2024,196:112571.
[14]	Zhang Q, Lei S, Zhang Q, et al. Establishment of a prognostic model for hospitalized cirrhotic patients with infection based on lumbar muscle mass[J]. Heliyon, 2024, 10(4):e25739.
[15]	Yao J, Zhou X, Yuan L, et al. Prognostic value of the third lumbar skeletal muscle mass index in patients with liver cirrhosis and ascites[J]. Clin Nutr, 2020, 39(6):1908-1913. doi: S0261-5614(19)33018-3 pmid: 31472986
[16]	Zhang S, Zhou T, Wu M, et al. Sarcopenia is associated with new-onset acute biliary infection within 1 year in patients with hepatitis B virus-related decompensated cirrhosis[J]. Eur J Gastroenterol Hepatol, 2025, 37(1):100-105.
[17]	Br VK, Sarin SK. Acute-on-chronic liver failure: Terminology,mechanisms and management[J]. Clin Mol Hepatol, 2023, 29 (3): 670-689.
[18]	Wang J, Bai J, Wang H, et al. Relationship between skeletal muscle index at the third lumbar vertebra with infection risk and long-term prognosis in patients with acute-on-chronic liver failure[J]. Front Nutr, 2024,10 1327832.
[19]	Geng N, Kong M, Zhang J, et al. Dynamic skeletal muscle loss and its predictive role on 90-day mortality in patients with acute-on-chronic liver failure[J]. Front Nutr, 2025,12: 1446265.
[20]	中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 中华肝脏病杂志, 2024, 32(5):418-434.
[21]	Teng ML, Ng CH, Huang DQ, et al. Global incidence and prevalence of nonalcoholic fatty liver disease[J]. Clin Mol Hepatol, 2023, 29(Suppl):S32-S42.
[22]	Roh E, Hwang SY, Yoo HJ, et al. Impact of non-alcoholic fatty liver disease on the risk of sarcopenia: A nationwide multicenter prospective study[J]. Hepatol Int, 2022, 16(3):545-554.
[23]	Feng Z, Zhao F, Wang Z, et al. The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations[J]. BMC Gastroenterol, 2024, 24(1):111. doi: 10.1186/s12876-024-03192-0 pmid: 38491346
[24]	Harring M, Golabi P, Paik JM, et al. Sarcopenia among patients with nonalcoholic fatty liver disease (NAFLD) is associated with advanced fibrosis[J]. Clin Gastroenterol Hepatol, 2023, 21(11):2876-2888.e5.
[25]	Zhao Q, Yin Y, Deng Y. Metabolic associated fatty liver disease and sarcopenia additively increase mortality: A real-world study[J]. Nutr Diabetes, 2023, 13(1):21. doi: 10.1038/s41387-023-00250-6 pmid: 37968264
[26]	Hsieh YC, Joo SK, Koo BK, et al. Muscle alterations are independently associated with significant fibrosis in patients with nonalcoholic fatty liver disease[J]. Liver Int, 2021, 41(3):494-504.
[27]	Lee YK, Koo BK, Joo SK, et al. Low-quality muscle mass rather than normal-quality muscle mass determines fibrosis progression in biopsy-proven NAFLD[J]. Aliment Pharmacol Ther, 2023, 58(3):322-333.
[28]	原发性肝癌诊疗指南(2024年版)[J]. 肿瘤综合治疗电子杂志, 2024, 10(3):17-68.
[29]	Yang S, Zhang Z, Su T, et al. CT-based skeletal muscle loss for predicting poor survival in patients with hepatocellular carcinoma experiencing curative hepatectomy plus adjuvant transarterial chemoembolization: A preliminary retrospective study[J]. Eur J Med Res, 2022, 27(1):131. doi: 10.1186/s40001-022-00760-6 pmid: 35879734
[30]	Wang X, Wang J, Li J, et al. Effect of skeletal muscle index on post-embolization syndrome of hepatocellular carcinoma after transarterial chemoembolization[J]. BMC Gastroenterol, 2024, 24(1):333. doi: 10.1186/s12876-024-03427-0 pmid: 39350028
[31]	Polvieng T, Hongjinda S, Thienhiran A, et al. Effect of sarcopenia on the prognosis of clinical outcomes in patients with hepatocellular carcinoma after hepatic resection[J]. Am Surg, 2024, 90(6):1447-1455. doi: 10.1177/00031348241241713 pmid: 38516765
[32]	Akaoka M, Haruki K, Taniai T, et al. Clinical significance of cachexia index in patients with hepatocellular carcinoma after hepatic resection[J]. Surg Oncol, 2022,45:101881.
[33]	Matsunaga T, Satio H, Sakano YU, et al. Skeletal muscle mass before second-line chemotherapy correlates with subsequent prognosis and rate of late-line chemotherapy in patients with unresectable gastric cancer[J]. Anticancer Res, 2023, 43(11):5051-5059. doi: 10.21873/anticanres.16704 pmid: 37909949
[34]	Alnimri F, Sivakumar J, Sutherland T, et al. Pre-operative low muscle mass is associated with major complications and lower recurrence-free survival after gastric cancer surgery[J]. ANZ J Surg, 2021, 91(3):316-322.
[35]	Juez LD, Priego P, Bajawi M, et al. Impact of sarcopenic obesity on long-term cancer outcomes and postoperative complications after gastrectomy for gastric cancer[J]. J Gastrointest Surg, 2023, 27(1):35-46.
[36]	Ma Z, Liu R, Liu H, et al. New scoring system combining computed tomography body composition analysis and inflammatory-nutritional indicators to predict postoperative complications in stage II-III colon cancer[J]. J Gastroenterol Hepatol, 2023, 38(9):1520-1529.
[37]	Raoul P, Cintoni M, Coppola A, et al. Preoperative low skeletal muscle mass index assessed using L3-CT as a prognostic marker of clinical outcomes in pancreatic cancer patients undergoing surgery: A systematic review and meta-analysis[J]. Int J Surg, 2024, 110(10):6126-6134.
[38]	Grillot J, D'Engremont C, Parmentier AL, et al. Sarcopenia and visceral obesity assessed by computed tomography are associated with adverse outcomes in patients with Crohn's disease[J]. Clin Nutr, 2020, 39(10):3024-3030. doi: 10.1016/j.clnu.2020.01.001 pmid: 31980183
[39]	Wang R, Ding X, Tian Z, et al. Body composition changes and related factors in patients with ulcerative colitis: A retrospective single-center study in China[J]. Med Sci Monit, 2022,28:e933942.
[40]	中华医学会外科学分会胰腺外科学组. 中国急性胰腺炎诊治指南(2021)[J]. 浙江实用医学, 2021, 26(6):511-519,535.
[41]	Lin C, Zhang J, Wang C, et al. The impact of skeletal muscle index at the third lumbar spine on nosocomial deterioration and short-term prognosis in acute pancreatitis:Aretrospective observational study[J]. PeerJ, 2024,12:e17283.
[42]	Xu L, Yu H, Chen L, et al. The modified computed tomography severity index combined with low skeletal muscle mass can better predict the severity of hypertriglyceridemia-induced pancreatitis[J]. J Hepatobiliary Pancreat Sci, 2022, 29(12):1336-1345.

第三腰椎骨骼肌指数在消化系统疾病中的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 42

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈颖新, 王韶轩. JAK/STAT信号通路在消化系统疾病中的研究进展[J]. 临床荟萃, 2024, 39(12): 1125-1130.
[2]	胡英1，王静1，高天2. 幽门螺杆菌感染诊治策略探讨[J]. 临床荟萃, 2020, 35(8): 745-748.
[3]	尔丽绵1, 冯志杰2. 超声内镜造影增强技术在消化系统疾病诊治中的应用[J]. 临床荟萃, 2019, 34(9): 790-794.
[4]	宋佳，罗雨欣，郭金波，张晓岚. 2018年消化系统疾病主要临床进展[J]. 临床荟萃, 2019, 34(1): 41-48.
[5]	王冬，罗雨欣，尹凤荣，张晓岚. 2017年消化系统疾病主要临床进展[J]. 临床荟萃, 2018, 33(1): 23-31.
[6]	张晓岚，郭金波，韩菲，牛巍巍，罗雨欣. 2016年消化系统疾病主要临床进展[J]. 临床荟萃, 2017, 32(2): 121-131.
[7]	邢洁，张澍田. 第十三届北京国际消化疾病论坛会议纪要[J]. 临床荟萃, 2016, 31(7): 781-781.
[8]	张晓岚,郭金波,尹凤荣. 2015年消化系统疾病主要临床进展[J]. 临床荟萃, 2016, 31(2): 131-142.
[9]	张晓岚;郭金波;尹凤荣. 2014年消化系统疾病临床进展[J]. 临床荟萃, 2015, 30(2): 142-149156.
[10]	张晓岚;郭金波;尹凤荣. 2013年消化系统疾病主要临床进展[J]. 临床荟萃, 2014, 29(5): 481-489.
[11]	张晓岚;牛国超;郭金波. 2012年消化系统疾病主要临床进展[J]. 临床荟萃, 2013, 28(5): 481-487491.
[12]	张晓岚;刘蕾;牛国超. 2011年消化系统疾病主要临床进展[J]. 临床荟萃, 2012, 27(8): 645-651656.
[13]	张玉斗;袁霞. 硒在消化系统疾病防治中的应用[J]. 临床荟萃, 2012, 27(3): 263-266.
[14]	吴正奇;张志镒;卢林芝;卢翠玲;王希萍;张丽萍;吴翠花. 治疗性经内镜逆行胰胆管造影的安全性及疗效226例分析[J]. 临床荟萃, 2012, 27(23): 2072-2074.
[15]	张晓岚;安君艳. 2010年消化系统疾病重要诊疗进展[J]. 临床荟萃, 2011, 26(9): 737-742.